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P2X receptors for ATP are ligand gated cation channels that form from the trimeric assembly of subunits with two transmem-
brane segments, a large extracellular ligand binding loop, and intracellular amino and carboxy termini. The receptors are
expressed throughout the body, involved in functions ranging from blood clotting to inﬂammation, and may provide
important targets for novel therapeutics. Mutagenesis based studies have been used to develop an understanding of the
molecular basis of their pharmacology with the aim of developing models of the ligand binding site. A crystal structure for the
zebra ﬁsh P2X4 receptor in the closed agonist unbound state has been published recently, which provides a major advance in
our understanding of the receptors. This review gives an overview of mutagenesis studies that have led to the development of
a model of the ATP binding site, as well as identifying residues contributing to allosteric regulation and antagonism. These
studies are discussed with reference to the crystal to provide a structural interpretation of the molecular basis of drug action.
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Perspective and functional roles of P2X receptors
ATP is more than just an intracellular energy carrier, it is an
extracellular transmitter binding to, and activating ligand
gated P2X receptors and G-protein coupled P2Y receptors
(Burnstock and Kennedy, 1985; Dubyak, 1991; Abbracchio
and Burnstock, 1994). P2 purinergic receptors were ﬁrst pro-
posed in the 1970s by Professor Geoffrey Burnstock (for a
historical review, see Burnstock, 2006a), have subsequently
been shown to be expressed in almost all cell types, and
mediate functions from taste sensation to the recruitment of
phagocytes to apoptotic cells (Finger et al., 2005; Elliott et al.,
2009). The seven mammalian P2X subunits (P2X1-7)
assemble as homomeric and heteromeric receptors with a
range of phenotypes (North, 2002; Egan et al., 2004; Roberts
et al., 2006). Pharmacological proﬁling, expression analysis, as
well as knockout and knock-down approaches have deﬁned
the contributions of P2X receptors in native systems and
suggested that P2X receptor selective drugs will be useful
in the treatment of a variety of conditions including
thromboembolism, bladder instability, pain and inﬂamma-
tion (Roberts et al., 2006; Burnstock, 2006b; Surprenant and
North, 2009). The recent publication of a crystal structure of
the zebra ﬁsh P2X4 (zP2X4) receptor in a closed agonist-
unbound state (Kawate et al., 2009) is a major advance for the
understanding of P2X receptors. This review focuses on the
molecular basis of P2X receptor pharmacological properties
and how the crystal structure expands our understanding of
the channel.
Pre-crystalization structural insight
P2X receptors were originally identiﬁed at the molecular level
by expression cloning from the vas deferens and phaeochro-
mocytoma (PC12) cells (Brake et al., 1994; Valera et al., 1994).
These receptors had no sequence homology with other ion
channels, so bio-informatic and molecular/biochemical
studies were ﬁrst used to develop an understanding of the
receptor structure. Sequence and hydrophobicity analysis sug-
gested the P2X receptor subunit had two transmembrane
(TM) segments, intracellular amino and carboxy termini and
a large extracellular ligand binding loop (Brake et al., 1994;
Valera et al., 1994). This topology was supported by immuno-
histochemical (Vulchanova et al., 1996), mutagenesis (Buell
et al., 1996), and glycosylation studies (Newbolt et al., 1998;
Torres et al., 1998) (for review, see North, 2002). Like the other
families of ligand gated ion channels (LGICs), P2X receptors
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www.brjpharmacol.orgform as multimers. Evidence for this came initially from
studies co-expressing slowly desensitizing a,b-meATP-
insensitive P2X2 receptors, and rapidly desensitizing a,b-
meATP-sensitive P2X3 receptor subunits. This gave rise to a
novel P2X2/3 heteromeric receptor that had the slowly desen-
sitizing time course of the P2X2 receptor and the a,b-meATP
sensitivity of the P2X3 receptor subunit (Lewis et al., 1995).
The subunit stochiometry was subsequently shown to be a
trimer by Nicke et al. (Nicke et al. 1998) based on the size of
P2X receptors in Western blot studies using native blue gels or
of cross-linked receptors. This agreed well with early predic-
tions that three molecules of ATP were required to activate the
channel (Bean, 1990), and also with subsequent models of
opening based on single channel analysis (Ding and Sachs,
1999). These studies showed the stoichiometry and topology
of P2X receptors was distinct from the pentameric nicotinic/
cys loop and the tetrameric glutamate families of ionotropic
receptors, which possess four and three membrane spanning
segments, respectively, per subunit (Surprenant et al., 1995).
P2X receptors are therefore a third structural class of LGIC
that form as trimers from subunits with two transmembrane
segments, intracellular amino and carboxy termini, and a
large extracellular loop.
Prior to a high-resolution crystal structure of the P2X recep-
tor, predictions about tertiary structure came from cysteine
mutagenesis studies. There are 10 conserved cysteine residues
in the extracellular domain of mammalian P2X receptors that
could form disulphide bonds and constrain the receptor struc-
ture. Cysteine reactive (2-aminoethyl) methanethiosulfonate
hydrobromide-biotin was unable to bind to wild-type P2X1
receptors suggesting that no free cysteine residues were acces-
sible (Ennion and Evans, 2002). However, biotinylation was
detected when individual cysteine residues were mutated, as
predicted if a cysteine to alanine mutation disrupted a disul-
phide bond pairing and exposed the free cysteine binding
partner (Ennion and Evans, 2002). Single cysteine mutants
also changed P2X receptor pharmacological properties, with
similar effects for pairs of cysteine mutants (Clyne et al.,
2002b; Ennion and Evans, 2002). These ﬁndings suggested
that disulphide bonds formed between cysteines 1–6, 2–4, 3–5,
7–8 and 9–10 in the extracellular domain (Ennion and Evans,
2002; Clyne et al., 2002b). The disulphide bonding of the ﬁrst
six cysteine residues in the extracellular domain predicted the
formation of a ﬁnger-like motif. Interestingly, mutation of
several residues within this region reduced the allosteric
effects of divalent cations and protons on ATP-evoked currents
(for review, see Evans, 2009), and mutation of the cysteines
abolished regulation by zinc at P2X2 receptors (Clyne et al.,
2002b). This suggests that the cysteine-bonded ﬁnger forms an
allosteric regulatory domain. The co-expression of mutations
that introduced additional cysteine residues into the extracel-
lular domain can result in disulphide bond formation between
adjacent subunits when the introduced residues are sufﬁ-
ciently close and in the correct orientation. This method
provided information on the proximity of residues in adjacent
subunits (Jiang et al., 2003) and suggested that the ATP
binding and regulatory allosteric sites are formed at the inter-
face between P2X receptor subunits (Nagaya et al., 2005;
Marquez-Klaka et al., 2007) (see below for details). Cysteine
mutagenesis studies have therefore been useful in providing
the ﬁrst insight into P2X receptor structural constraints and
molecular distances between residues.
The ﬁrst glimpses of the P2X receptor 3D structure came
following receptor puriﬁcation, atomic force microscopy and
cryo-EM. These studies support the trimeric assembly of the
receptor (Barrera et al., 2005; Mio et al., 2005; Nakazawa et al.,
2005; Young et al., 2008). Recently, a structure at 15 Å resolu-
tion for the P2X2 receptor has been published (Mio et al.,
2009). These structures showed that the receptor has three-
fold symmetry, a globular extracellular domain, and identi-
ﬁed interactions between the intracellular amino and carboxy
termini.
Crystalization of the zebra ﬁsh P2X4 receptor
The crystallization of membrane proteins is difﬁcult and often
requires modiﬁcations of the receptor to be made. The zP2X4
receptor took 7 years to solve (Silberberg and Swartz, 2009)
requiring truncation, mutation and considerable patience
(the DP2X4-B mutant alone took 9 months for the crystals to
grow (Kawate et al., 2009). This crystal structure conﬁrms the
receptor topology, that it is a trimer with threefold symmetry,
and also shows that the extracellular domain projects 70 Å
above the cell surface. The TM regions are shaped like an
hourglass and are similar to those of the two TM segment
trimeric acid sensing ion channel (ASIC) (Gonzales et al.,
2009). In the extracellular domain, the three P2X receptor
subunits are entwined with a right-handed twist (Figure 1A),
and there are three vestibules in the centre of the extracellular
domain. This crystal structure also conﬁrms the predicted
disulphide bonding pattern of the receptor and the existence
of a cysteine-rich ﬁnger domain. An excellent review of the
structural information and comparison with other P2X recep-
tor structures has been published recently (Young, 2009). The
zP2X4 receptor was crystallized in the absence of ligand, and
no conﬁrmation was given that the puriﬁed protein could
bind agonists or antagonists. The structure therefore provides
no direct information on ATP binding, and this should be
borne in mind as a caveat for interpretation. However, a
possible agonist binding site was proposed based on previous
mutagenesis studies. The remainder of the review summarizes
the information available on ligand action and regulation
from mutagenesis studies and discusses its interpretation in
light of the zP2X4 receptor crystal structure.
Mutagenesis based predictions of the ATP
binding site
Analysis of a wide range of proteins has identiﬁed several
consensus motifs for ATP binding. For example, the Walker
GXXXXGKT/S motif (X denotes any residue) can coordinate
binding of the phosphate of ATP (Walker et al., 1982), and a
Q-motif comprising a conserved glutamine and an aromatic
amino acid 17 amino acids upstream can contribute to
adenine binding (Tanner et al., 2003). However, such consen-
sus motifs for ATP binding are not present in the P2X receptor
family. Consequently a mutagenesis-based approach was used
to determine the site of agonist action. Alanine is widely used
P2X receptor mutants and structure
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is well tolerated as a substitution. Initial studies focused on
determining the effects of alanine mutations of conserved
basic, aromatic and polar amino acids in the extracellular
domain (Figure 2). The assumption being that as all the P2X
receptors are activated by ATP, it is likely that they share a
common core ATP binding site.
Positively charged amino acids are involved in coordinating
the binding of the negatively charged phosphates of ATP.
Mutants generated on P2X1 and P2X2 receptor backgrounds
showed that residues Lys68, Lys70, Arg292 and Lys309 con-
tribute to ATP potency (P2X1 receptor numbering)(Ennion
et al., 2000; Jiang et al., 2000); with the greatest, >1000-fold,
decreases in ATP sensitivity for Lys68Ala and Lys309Ala
mutants at the P2X1 receptor (Ennion et al., 2000). Aromatic
amino acids bind the adenine ring of ATP in DEAD box
helicases (Tanner et al., 2003) and the ribose of ATP in UvrB
DNA helicase (Theis et al., 1999). Mutagenesis of conserved
aromatic amino acids in the P2X1 receptor demonstrated a
contribution of Phe185 and Phe291 in agonist action (Roberts
and Evans, 2004), with ~10 and 140-fold reduction in ATP
potency following alanine replacement mutagenesis respec-
tively. Polar amino acids can also contribute to agonist
binding, and mutagenesis studies on P2X1 and P2X2 recep-
tors highlighted a role of Thr186 and Asn290 (P2X1 receptor
numbering) in ATP sensitivity (Jiang et al., 2000; Roberts and
Evans, 2006).
To date, more than 120 of the ~280 amino acids in the
extracellular domain of the human P2X1 receptor, including
over 60 conserved residues, have been mutated to alanine
and/or cysteine (Evans, 2009; Roberts et al., 2009) (Figure 2).
The majority of these mutants had little or no effect on ATP
potency; only eight of the mutants made substantial contri-
butions to ATP sensitivity. Based on these studies, a model
of how ATP binds to the receptor was proposed (Figure 1C),
with lysine residues 68, 70 and 309 coordinating the binding
of the negatively charged phosphate tail of ATP. Binding of
the adenine ring may be coordinated by the aromatic
region Asn290Phe291Arg292, with a regulatory role of
Phe185Thr186 possibly by hydrogen bonding (all P2X1 recep-
tor numbering) (Roberts et al., 2006; Roberts et al., 2009). The
amino acids proposed in the model are conserved across
mammalian P2X receptors, with similar effects of mutations
of these residues reported for P2X2 and P2X4 receptors (Jiang
et al., 2000; Zemkova et al., 2007; Roberts et al., 2008), sug-
gesting a common core ATP binding pocket.
The predicted ATP binding site is formed from four discrete
clusters of amino acids (corresponding to residues 68, 70, 185,
292
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Figure 1 Crystal structure of the zebra ﬁsh P2X4 (zP2X4) receptor and the proposed sites for agonist and antagoinist binding. (A) Homology
model of the human P2X1 receptor based on the structure of the zP2X4 receptor (Kawate et al., 2009) showing the three entwined subunits
in grey, black and slate blue; the black box indicates the region incorporating residues involved in agonist and antagonist action and in more
detail in panels B–D. (B) Residues predicted to form the ATP binding pocket are shown in red (P2X1 receptor numbering), the blue residue
corresponds to an Arg residue in P2X7 that can be ADP ribosylated and activate the channel. Mutations that affect sensitivity to PPADs and
suramin are shown in orange and yellow, respectively. (C) Most recent model of ATP binding at the P2X1 receptor based on mutagenesis
studies (adapted from Roberts et al., 2009); light grey for Phe185 indicates that the cysteine mutant at this position had no effect on ATP
potency, and although this residue was accessible to (2-aminoethyl) methanethiosulfonate hydrobromide-biotin, MTS reagents did not affect
ATP-evoked responses, suggesting that this residue does not directly into the agonist binding pocket. Similarly, Phe291 is shown in grey as MTS
reagents did not modify ATP evoked responses at P2X2 and P2X4 receptors (Roberts et al., 2008). (D and E) Rotations clockwise of the structure
highlighted in (B) give an indication of the 3D proximity of the residues showing that Lys residue 138 shown to regulate suramin sensitivity
is close to the proposed ATP binding pocket, but the side chain faces away from it on the other side of the cysteine rich head group. The ﬁgures
were generated and re-coloured using PyMOL (DeLano Scientiﬁc, Palo Alto, CA, USA) and the structure 3H9V as a template for the hP2X1
receptor homology model. PPADs, pyridoxal 5-phosphate 6-azophenyl-2′,4′-disulphonic acid.
P2X receptor mutants and structure
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by 115, 104 and 17 residues. This implies that the receptor
must be folded/assembled in such a way as to bring these
regions close together. The proximity of two of these clusters
has been conﬁrmed by cysteine replacement mutagenesis in
the P2X1 receptor, which showed cysteine mutants of Lys68
and Phe 291 were sufﬁciently close to form a disulphide bond.
This bond formed between adjacent subunits, and was inhib-
ited in the presence of ATP (Marquez-klaka et al., 2007). These
results, in addition to supporting the model, also provide
evidence that the ATP binding site forms at the interface
between adjacent subunits, as had been suggested from
studies on lysine mutants in P2X2/3 receptor heteromers
(Wilkinson et al., 2006).
Compatibility of mutagenesis based model for the
ATP binding site and structural data
Although the zP2X4 receptor was crystallized in the absence
of ATP (Kawate et al., 2009), it does allow mutagenesis studies
to be interpreted in a structural context and highlights a
region that incorporates several residues important for deter-
mining P2X receptor pharmacological properties. The zP2X4
receptor crystal structure shows that the eight conserved resi-
dues predicted to contribute to the ATP binding site are
indeed in close proximity (Kawate et al., 2009), and this has
also been found for a homology model of the P2X1 receptor
(Lys68, Lys70, Phe185, Thr 186 from one subunit, and
Asn290, Phe291, Arg292 and Lys309 in the adjacent one;
P2X1 receptor numbering, Figure 1) and P2X2 receptors
(Keceli and Kubo, 2009; Kubo et al., 2009). Further support
that this region forms the agonist binding site comes from (i)
the substantial effects of mutations of only these residues on
ATP potency (Jiang et al., 2000; Zemkova et al., 2007; Roberts
et al., 2008) and radioligand binding (Roberts and Evans,
2004; Roberts et al., 2009); (ii) the presence of the only con-
served basic residues that are involved in determining agonist
sensitivity (Lys 68, 70, 309, and Arg292 P2X1 numbering); it
would be extraordinary if the ATP binding pocket did not
include positively charged amino acids to coordinate the
binding of the negatively charged phosphates; and (iii) resi-
dues involved in both allosteric regulation and antagonist
action form a halo around this region (Figure 3, see later).
These lines of evidence, though compelling, are circumstan-
tial and do not directly prove the location of the ATP binding
site. Studies on the P2X7 receptor, however, provide direct
evidence to substantiate the location of agonist binding site.
ADP-ribosyltransferases transfer ADP-ribose from NAD onto
proteins and ADP-ribosylation at Arg125 activates P2X7
receptors (Adriouch et al., 2007). Furthermore, in the zP2X4
receptor structure, the equivalent residue to Arg 125 is adja-
cent to the predicted ATP binding pocket. This suggests that
ADP tethered by ribosylation to Arg125 on the P2X7 receptor
can access that adjacent ATP binding pocket and activate the
receptor (Adriouch et al., 2007; Schwarz et al., 2009).
If the region predicted to be the ATP binding site is correct,
what insight does the zP2X4 receptor structure give to inter-
pretation of mutagenesis studies and development of the
model? In the model, it seems most likely that the conserved
lysine residues contribute to binding of the phosphate of ATP
as cysteine mutants of these residues show that ATP potency
can be increased by positively charged MTS reagents and
reduced by negatively charged MTS reagents (Roberts and
Figure 2 Conserved amino acids in the extracellular domain of mammalian P2X receptors and the effects of P2X1 receptor mutants on ATP
potency. Amino acid sequences of the extracellular domain of human P2X1, 2 and 4 receptors are shown. Residues that are conserved in at
least ﬁve mammalian P2X receptor subunits are shown for basic (red), aromatic (purple), polar (green), glycine/proline (yellow), and cysteine,
valine, alanine, aspartate and glutamate (black). The top lines (mutants) show in bold and colour the conserved residues, which, when
mutated, have a substantial effect on ATP potency and have been incorporated into the binding site model. In addition, alanine or cysteine
point mutations that have no or a less than 10-fold effect on ATP potency are shown as dashes; non-conserved residues are in lower case.
P2X receptor mutants and structure
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zP2X4 receptor, it is clear that the conserved lysine residues
are not buried within the protein, but are exposed on the
surface within the predicted binding groove, raising the pos-
sibility that substitutions at the phosphate end of the ATP
molecule could easily be accommodated. Support that the
region around the terminal phosphate is open at the protein
surface and comes from ADP ribosylation (see above)(Adri-
ouch et al., 2007). In addition, the ATP analogues adenosine
tetraphosphate and diadenosine pentaphosphate (Ap5A) are
agonists at some, but not all P2X receptors, showing that
bulky substitutions, such as the addition of an ADP to ATP to
make Ap5A, can be accommodated at the P2X1 receptor
binding pocket (Ralevic et al., 1995; Lewis et al., 2000). These
results suggest that the terminal phosphate of ATP faces out of
the binding pocket, and the adenine and ribose components
of ATP are bound deeper within the protein or further along
the binding groove.
Phenylalanines can form part of a motif for adenine
binding (Tanner et al., 2003). Phe291 (P2X1 receptor number-
ing) was suggested to bind the adenine ring of ATP as muta-
tion decreased agonist potency at P2X1, 2 and 4 receptors
(Roberts and Evans, 2004; Roberts et al., 2008). Interestingly,
CTP is also a weak agonist at P2X receptors (Chen et al., 1995;
Soto et al., 1996; Roberts and Evans, 2004), although whether
the pyrimidine ring binds in the same way as adenine remains
to be determined. The zP2X4 receptor shows that the con-
served phenylalanine predicted to be involved in agonist rec-
ognition is the residue in the model that is farthest from the
outer surface of the receptor (Kawate et al., 2009). This sup-
ports results from mutagenesis studies at P2X2 and P2X4
receptors, where cysteine mutants of these residues were not
affected by MTS reagents and were considered inaccessible to
these compounds (Roberts et al., 2008). However, at P2X1
receptors, Phe291Cys was inhibited by both positive and
negatively charged MTS reagents demonstrating accessibility
and suggesting that it contributes to the ATP binding pocket.
These differences between P2X receptors suggest that there
are subtle variations in geometry between receptor subtypes.
At P2X1 receptors, the accessibility of Phe291Cys is consistent
with the disulphide bond that can form between Phe291Cys
and Lys68Cys in an adjacent subunit (Marquez-Klaka et al.,
2007). However, disulphide bond formation for equivalent
mutations was less efﬁcient for P2X2 receptors, and a
bi-functional cysteine reactive cross-linker was required to
form disulphided receptor dimers for P2X3 and P2X4 recep-
tors (Marquez-klaka et al., 2009). Such differences in structure
between receptors may be important in determining the
subunit dependent pharmacological properties.
The predicted roles for the lysines 68, 70 and 309 in phos-
phate binding and phenylalanine 291 in binding the adenine
ring suggests that Asn290 and Arg292 could be involved coor-
dinating the binding of the ribose of ATP. The original model
developed from P2X1 receptor mutagenesis studies also incor-
porated Phe185 Thr186, since alanine mutants of these resi-
dues decreased ATP potency (Roberts and Evans, 2004;
Roberts & Evans, 2006). The 10-fold decrease in ATP potency
for Phe185 with alanine substitution was modest (Roberts and
Evans, 2004), and there was no change in sensitivity for the
cysteine mutant (Roberts et al., 2009). In addition for the
Phe185Cys mutant ATP potency was not changed by applica-
tion of cysteine reactive MTS reagents even though they are
able to bind to the receptor (Roberts et al., 2009). Similarly, at
P2X2 and P2X4 receptors, the equivalent cysteine mutants
pH P2X7
Gd3+ P2X4
ATP
Arg304P2X2
Zn2+ P2X2
Asp259 P2X2
His319 P2X2
His206 P2X3
Lys190 P2X4
Arg278 P2X4
Asp280 P2X4
Arg206 P2X7
Figure 3 Mapping of residues involved in gating and ionic regulation to the P2X receptor structure. An homology model of the hP2X1
receptor built using the zebra ﬁsh P2X4 (zP2X4) receptor structure. Left-hand panel shows a surface rendered representation of the P2X
receptor, and right panel shows a stick diagram of the receptor for residues shown to be involved in the binding of ATP (red), gadolinium
(green), regulation by zinc (cyan) and pH (magenta). Residues where mutation decreased ATP potency, but the effects were not conserved
across subunits, suggesting that the effects result from disruption of interaction with a variant amino acids, are shown in blue. The residues
associated with gadolinium and zinc action are clustered around the ATP binding site, and those with pH and gating regulation either side of
the ATP binding region with a concentration in a halo just below the ATP binding site.
P2X receptor mutants and structure
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results suggest that the conserved residue Phe185 (P2X1
receptor numbering) does not directly interact with ATP at
the binding pocket. At the adjacent conserved threonine
residue, cysteine mutants had modest effects on ATP potency,
and were sensitive to MTS reagents at P2X1, 2 and 4 receptors
(Roberts et al., 2008; Roberts et al., 2009). This suggests that
the conserved threonine contributes to ATP action. From the
zP2X receptor structure, the PheThr doublet is adjacent to a
conserved lysine residues, and Thr186 may therefore play a
role in ﬁne tuning the interaction of the phosphate tail of ATP
with Lys70.
The binding of ATP to the P2X receptor results in confor-
mational changes that lead to the opening of the channel
pore (gating of the channel). The zP2X4 receptor structure
shows that the proposed ATP binding site is ~45 Å from the
channel pore, and it is unclear how agonist binding leads to
the conformational changes that underlie opening/gating of
the channel. Changes in ATP potency at mutant P2X recep-
tors can arise from an effect on agonist binding and/or gating
of the receptor. A radiolabelled 2-azido ATP binding assay was
used to give insight into the interpretation of mutagenesis
studies (Roberts and Evans, 2007). Binding of 2-azido ATP was
reduced for cysteine mutants of Asn290, Phe291, Arg292 and
Lys309 at the P2X1 receptor. However, the extent of the
reduction did not mirror exactly the changes in ATP potency.
Binding was reduced by ~50% for Asn290Cys and Phe291Cys,
which showed ~50-fold reduction in ATP potency, while
binding was reduced by >80% for Arg292Cys and Lys309Cys,
which had 15- and 180-fold reductions in potency respec-
tively (Roberts and Evans, 2007). These discrepancies between
the changes in potency and binding can be explained by an
effect on gating. The reduced potency at Arg292Cys may have
resulted predominantly from an effect on binding (Roberts
and Evans, 2007). In contrast, for the cysteine mutants
Asn290 and Phe292, an effect on binding and also a reduction
in gating seemed likely (Roberts and Evans, 2007). For
Lys309Cys, the level of binding was on the limit of detection,
and, compared with the smaller potency change of
Arg292Cys with equivalent reduction in binding, suggested
that a gating effect was also involved (Roberts and Evans,
2007). This was supported by single channel studies suggest-
ing a gating role of the equivalent lysine residue in the P2X2
receptor (Cao et al., 2007). These results indicate that residues
within the binding pocket play a central role in transforming
agonist binding into opening of the P2X receptor channel.
Interpretation of mutations that have an effect on
ATP potency, but do not ﬁt the proposed model
for agonist binding
The effects of some conserved amino acid mutations do not ﬁt
the proposed ATP binding site model (described above), and
can vary markedly between different P2X receptor subunits.
At P2X2 receptors, the Lys188Ala, Asp259Ala and Arg304Ala
mutations showed >300-fold decreases in ATP potency (Jiang
et al., 2000), whereas equivalent mutations at the P2X1 recep-
tor had no effect or a <10-fold decrease (Ennion et al., 2000;
Ennion et al., 2001). The P2X4 receptor mutants Lys190Ala
and Phe230Ala were essentially insensitive to ATP (Yan et al.,
2005), while the equivalent alanine mutants had little or no
effect at P2X1 receptors (Ennion et al., 2000; Roberts and
Evans, 2004). At the mouse P2X7 receptor, mutation of the
conserved Arg206 to Lys resulted in an increase in ATP
potency (Schwarz et al., 2009), while the equivalent alanine
mutation at the P2X1 receptor R202A had no effect (Ennion
et al., 2000). These results highlight the importance of these
residues in some subunits. Why then if the residues are con-
served do they not show similar effects when mutated across
P2X receptor subunits? P2X receptors show a range of prop-
erties dependent on the subtype, and these differences result
from variations in amino acid sequence between the recep-
tors. This suggests that the subtype dependent effect of a
mutation of a conserved amino acid could also arise from an
important regulatory role of a non-conserved residue. For
example, at the P2X7 receptor, differences in amino acids at
residues 127 and 284 contribute to the variation in agonist
sensitivity between the rat and mouse isoforms (Young et al.,
2006). In addition, amino acid variations are likely to lead to
subtle differences in the structures of P2X receptor subunits
(as described above for the ability of cysteine mutants to form
disulphide bonds in different P2X receptor subunits
(Marquez-Klaka et al., 2009), which can contribute to the
heterogeneity in properties. Thus structural variations/non-
conserved residues are likely to account for the subunit
dependent differences in effects of conserved mutations and
mediate the heterogeneity in pharmacological properties
between receptor subtypes.
But how can these mutants result in a change in ATP sen-
sitivity when they are not part of the proposed ATP binding
site? One explanation is that the residues are involved in
conformational changes following agonist binding that lead
to the opening/gating of the P2X receptor ionic pore. Inter-
estingly, mapping these residues onto the P2X receptor struc-
ture shows the majority are located in a ring below the
proposed ATP binding pocket (Figure 3). This region provides
the link between the ATP binding pocket and the channel
pore and changes in properties could affect gating of the
channel and ligand sensitivity. As the residues are in different
stretches of the protein, it also suggests that interactions
between portions are important and the whole region may
undergo structural rearrangement following agonist binding
and, signiﬁcant movement in this region may provide the
transition to open the channel gate.
Allosteric modulatory sites
The binding of ATP to the P2X receptor orthosteric site can be
regulated by a number of allosteric agents, including divalent
cations and protons. For example, the sensitivity of ATP at
neuronal P2X receptors was increased by low concentrations
of zinc (Cloues et al., 1993; Li et al., 1993). Mutagenesis
studies have shown that histidine residues His120 and His213
underlie zinc potentiation at rat P2X2 receptors (Clyne et al.,
2002a; Lorca et al., 2005). Subsequent elegant studies showed
that cysteine mutants of these residues formed an inter-
subunit disulphide bond, demonstrating the close proximity
P2X receptor mutants and structure
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2005). Earlier work suggested that mutation of cysteine resi-
dues in the cysteine rich domain (incorporating cysteines 1-6)
disrupted zinc regulation, suggesting that disulphide bonds in
the cysteine rich ﬁnger domain stabilize the zinc binding site
(Clyne et al., 2002b; Coddou et al., 2007). The importance of
the cysteine rich region has also been shown for regulation by
copper (Coddou et al., 2007). It is tempting to speculate that
zinc could act to stabilize a conformational change associated
with ATP binding and thus increase agonist potency. The
P2X2 receptor double mutant His120Cys/His213Cys showed
barely detectable responses to ATP; however, on treatment
with the reducing agent, DTT currents were increased (Nagaya
et al., 2005). This suggests that the disulphide bond between
the introduced cysteines either restricted access of ATP to the
binding site or a conformational change associated with
binding, and/or gating. Interestingly, His120 in the P2X2
receptor is equivalent to Arg125 in the P2X7 receptor, which
is ADP ribosylated and can lead to receptor activation (Adri-
ouch et al., 2007), once again highlighting that this residue is
close to the ATP binding site. The zP2X4 receptor crystal
structure conﬁrms these predictions, and shows that the resi-
dues are in close proximity to the predicted ATP binding site
(Figure 1).
Trivalent cations can also have a regulatory role inhibiting
P2X receptor function (Nakazawa et al., 1997). Lanthanum
and gadolinium blocked P2X1 and P2X2 currents in oocytes;
this inhibition appeared competitive and was reversed by
increasing the ATP concentration (Nakazawa et al., 1997). The
crystal of the zP2X4 receptor was solved in the presence of
gadolinium, with residues Asp184 and Asn187 on the upper
outer region of the receptor, and Glu98 at the core vestibule,
coordinating the binding of the trivalent ion (Kawate et al.,
2009). Asn187 is just adjacent to Phe188Thr189, which are
thought to contribute to the ATP binding pocket, suggesting
that gadolinium binding at Asp 184 and Asn187 reduces ATP
afﬁnity. Interestingly, gadolinium increases recovery from
desensitisation at transient sensory P2X and rat P2X3 recep-
tors (Cook et al., 1998). At these receptors, recovery from
desensitisation and agonist unbinding were strongly linked
(Pratt et al., 2005). This indicates that gadolinium speeds the
unbinding of agonist from P2X3 receptors and is consistent
with an effect on reducing ATP afﬁnity. These results suggest
that the high (1 mM) gadolinium used in the receptor crys-
tallization may make it difﬁcult to solve the structure in an
ATP bound form.
Protons can also regulate P2X receptors with the effect
dependent on the channel subtype (Stoop et al., 1997). Histi-
dine residues mediate proton sensitivity at P2X2, 3, 4 and 7
receptors, although different residues are involved in each of
these subunits. At P2X2 receptors, the His319Ala mutation
reduced the potentiating effects of protons on ATP sensitivity
(Clyne et al., 2002a), while mimicking protonation of His319
with the His319Lys mutation increased ATP potency 40-fold.
Analysis of the structure for the zP2X4 receptor predicts that
His319 lines the vestibule formed at the centre of the receptor
(Figure 3) and could therefore contribute to channel gating.
In contrast, at P2X3 receptors, protons decrease ATP responses
(Stoop et al., 1997), and His206 contributes to proton sensi-
tivity, as well as recovery from desensitisation (Gerevich et al.,
2007). P2X4 receptors were also inhibited by protons, and
His286 mediates this effect (Clarke et al., 2000). Interestingly,
although different histidine residues are involved in proton
inhibition at P2X3 and P2X4 receptors, the residues are pre-
dicted to be on the surface of the receptor (Figure 3) in the
ring below the predicted ATP binding site, where mutants
may have an effect on ATP potency. This raises the possibility
that protonation of the histidine reduces gating and thus
potency (see above). At P2X7 receptors, His130 was involved
in proton sensitivity (Acuna-castillo et al., 2007), and this
residue forms part of the cysteine rich region (Figure 3) that
also contributes to divalent cation sensitivity.
Antagonist binding sites
P2X receptor antagonists have been suggested to have thera-
peutic potential in several diseases (Burnstock, 2006b) and a
range of subtype selective compounds have been described,
for example P2X1 receptor selective NF449 (Braun et al.,
2001) and P2X3 receptor selective A317491 (Jarvis et al.,
2002). However, our understanding of the molecular
basis of antagonist action is limited and focused on the
relatively non-selective antagonists pyridoxal 5-phosphate
6-azophenyl-2′,4′-disulphonic acid (PPADS) and suramin
(North and Surprenant, 2000).
PPADS acts non-competitively, and at high concentrations
depresses maximal responses to ATP. The rat P2X4 (rP2X4)
receptor is insensitive to commonly used antagonists (Buell
et al., 1996). PPADS can form a Schiff based with lysine resi-
dues, and a lysine present in PPADS sensitive P2X1 and P2X2
receptors is replaced by a glutamic acid residue in the rP2X4
receptor. Mutation of this glutamic acid residue at position
249 in the rP2X4 receptor to lysine recovered sensitivity to
PPADS (Buell et al., 1996). However, the reverse mutation in
the P2X2 receptor (Lys246Glu) did not remove PPADS inhi-
bition. Furthermore, this lysine residue is not present in
PPADS-sensitive human P2X3 and P2X7 receptors, and there-
fore other residues are also likely to contribute to the antago-
nist binding site (Buell et al., 1996). Subsequent cloning of the
human and mouse P2X4 receptors showed that they were
more sensitive to PPADS than the rat form (Garcia-Guzman
et al., 1997b; Jones et al., 2000); however, they showed essen-
tially identical amino acid sequence around residue 249, sug-
gesting that another region of the receptor was also involved
in determining PPADS sensitivity. A chimeric approach was
used to determine what was responsible for the PPADS sensi-
tivity differences between human and rat P2X4 receptors,
which showed residues in the region 81–183 also contribute
to PPADS sensitivity (Garcia-Guzman et al., 1997a). Species
differences in PPADS sensitivity at P2X7 receptors were also
utilized to generate chimeras and point mutations that iden-
tiﬁed a contribution of Arg126 to PPADS action (Michel et al.,
2008). The mutated residues shown to have an effect on
PPADS sensitivity are positively charged, which ﬁts with a role
in coordination of the negative charge of the antagonists
PPADS. Mapping these residues (equivalent to Arg 249 from
the P2X4 and 126 from the P2X7 receptor) onto a homology
model structure of the P2X1 receptor shows that they are
located either side of the proposed agonist binding site
P2X receptor mutants and structure
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therefore restrict access of ATP to its binding site and account
for its antagonistic effect.
Suramin appears to be a competitive antagonist, and
insight into its binding site has come from differences in
properties between species variants of P2X receptor subunits.
For the P2X4 receptor, point mutation showed residue 78 was
associated with differences between rat and human receptors;
for the mutant rat P2X4 Gln78Lys, the sensitivity was
increased ~10-fold (Garcia-Guzman et al., 1997a). However,
this was still >100-fold lower than suramin afﬁnity at the
hP2X1 receptor (Roberts and Evans, 2004), suggesting that
additional residues also contribute substantially to sensitivity.
The marked differences in sensitivity of human and mouse
P2X1 receptors to suramin have also been used to identify
Lys138 as contributing to the antagonist action of suramin
and its derivative NF449 that is effective at low nanomolar
concentrations (Braun et al., 2001; Sim et al., 2008). However,
this residue is not conserved among suramin sensitive recep-
tors, and it has been suggested that it is the localized positive
charge that is important in modulating the actions of the
negatively charged suramin (Braun et al., 2001; Sim et al.,
2008).
Suramin can act as a partial agonist at constitutively active
P2X2 receptors (Cao et al., 2007), and radioligand binding
studies have shown that suramin can competitively displace
radioligands from P2X receptors (Michel et al., 1996). This
raises the possibility that the same residues may be involved
in suramin and ATP binding. However, alanine mutants of the
conserved positively charged Lys, Arg and Phe residues in the
P2X1 receptor, which reduced ATP potency by >100-fold, had
little (Arg292Ala) or no effect (Lys68Ala, Lys70Ala and
Lys309Ala) (Ennion et al., 2000) or actually increased
(Phe291Ala) (Roberts and Evans, 2004) suramin sensitivity.
This shows that key residues involved in ATP potency do not
have an effect on suramin sensitivity, and indicate there is not
signiﬁcant overlap in the particular residues involved in
suramin and ATP binding. The homology model of the hP2X1
receptor also suggests that the mutants that can change
suramin sensitivity do not appear to interact directly with
residues that form the proposed ATP binding site. The Lys138
side chain, shown to regulate suramin sensitivity at the P2X1
receptor (Sim et al., 2008), does not line the ATP binding
pocket, but faces away from it and is on the other side of the
cysteine rich region (Figure 1). The proximity to, but not
direct interaction with the proposed ATP binding site, sug-
gests that suramin may act by stabilizing particular confor-
mational states of the receptor or its binding occludes
subsequent ATP binding and either of these mechanisms
could account for the competitive antagonism.
Suramin and PPADS are effective antagonists at most, but
not all P2X receptors. Therefore, it is likely that each antago-
nist may share key core conserved residues involved in
binding across subunits in addition to those residues described
above that can regulate sensitivity. However, whether this is
the case, or there is a more variable/diffuse binding site of
non-conserved residues in a general area remains to be deter-
mined. The zP2X4 receptor structure has given an insight into
where antagonists may act and highlights adjacent regions of
interest for future mutagenesis studies.
Transmembrane regions
Cysteine scanning mutagenesis studies showed that both TMs
could contribute to the permeation properties of P2X recep-
tors (Rassendren et al., 1997; Egan et al., 1998; Jiang et al.,
2001; Haines et al., 2001b; Li et al., 2008). Determination of
the rates of modiﬁcation of introduced cysteine residues sug-
gested that TM2 lined the pore and contained the channel
gate, and that TM1 was peripheral to the pore region (Li et al.,
2008). These predictions are supported by the zP2X4 receptor
structure (Kawate et al., 2009), and, interestingly, the arrange-
ment of the TMs is essentially the same as trimeric two TM
ASIC channels (Gonzales et al., 2009). While it is clear that the
TM2 region forms the ionic permeation pathway, TM1 also
contributes to control of the gating of the channel as shown
by a chimera of TM1 of P2X1 added to P2X2 increasing
sensitivity to a,b-methylene ATP (Haines et al., 2001a), and
the converse chimera with TM1 of P2X2 changing P2X1 from
a desensitizing to non-desensitizing phenotype (Rettinger and
Schmalzing, 2004). Elegant single-channel analysis of TM2
mutants have demonstrated residues that play a role in the
gating, single-channel conductance and rectiﬁcation of the
P2X2 receptor and have given an important insight into the
gate and channel opening of P2X receptors (Cao et al., 2007;
Cao et al., 2009). Studies on the P2X receptor TM domains
have clearly shown that they both play a role in determining
ATP responsiveness, and it is clear that TM derived differences
in gating between the receptors could contribute to the varia-
tion in agonist sensitivity.
Future directions
The structure of the zP2X4 receptor has provided a major
advance in our understanding of P2X receptors, insight into
the interpretation of mutagenesis studies and a model of
where ATP binds to the receptor. This review provides an
overview of mutagenesis studies on several P2X receptor sub-
units that supports a conserved consensus core ATP binding
pocket at P2X receptors, with the negative charge of the
phosphate groups coordinated by conserved Lys residues, and
an AsnPheArg motif the may regulate binding of the adenine
ring. The differences in ligand sensitivity between subunits
(for review, see North and Surprenant, 2000), however, dem-
onstrate clearly that variant amino acids also contribute to,
and regulate, pharmacological properties. The variation could
arise from single amino acid changes to disrupt gating and/or
interaction with the ligand, and/or involve more complex
structural changes as suggested by the variation in the
distance between introduced cysteine residues in different
subunits (Marquez-klaka et al., 2009). A range of studies,
including the use of differences in properties between species
orthologues, chimaeric receptors and mutations, have identi-
ﬁed residues that contribute to the heterogeneity of receptor
properties. However, to date, no clear picture has begun to
emerge on what underlies the variations in pharmacology, for
example the differences in ATP potency, why a,b-meATP is
effective at P2X1 and P2X3 but not other P2X receptor sub-
units, or the mechanism of action of selective antagonists.
Additional P2X receptor structures would provide another
P2X receptor mutants and structure
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and give an insight into subtype dependent differences. Of
particular interest would be structures with agonist or antago-
nist bound to develop models of drug action, aid in the
understanding of the subtype dependent basis of pharmaco-
logical properties, and gain insight into structural changes in
the receptor on activation. However, in their absence, there
are a number of areas that can be addressed. (i) Structural-
based modelling of drug action: Now that a structure for the
zP2X4 receptor is available, molecular-docking programmes
can be used to develop models of how ligand binding to the
receptor. These models could also be developed to understand
the structural basis for differences in pharmacology between
subunits and in rational drug design. (ii) Conformational
changes: The structure of zP2X4 is in the closed conformation
in the absence of ATP and provides a snapshot of one of the
conformations that the receptor can adopt. A major question
is how ATP binding leads to gating of the channel pore?
Techniques to look at changes in accessibility of regions of the
protein will be useful, and voltage clamp ﬂuorometry could
be used to give some temporal resolution to conformational
changes (Pless and Lynch, 2009). (iii) Intracellular domains:
Mutations in the intracellular domains can have profound
effects on the properties of P2X receptors, and how these are
transmitted to the rest of the channel remains to be deter-
mined. The association of P2X receptors with interacting pro-
teins (e.g. Kim et al., 2001) provides an added layer of
complexity to understand the molecular basis of how the
intracellular domains regulate channel function.
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